Allele percentage of the BRAF V600E mutation in papillary thyroid carcinomas and corresponding lymph node metastases: No evidence for a role in tumor progression

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 5, 2013, Pages

  Gandolfi, Greta ^a   Sancisi, Valentina ^a   Torricelli, Federica ^a   Ragazzi, Moira ^b   Frasoldati, Andrea ^c   Piana, Simonetta ^b   Ciarrocchi, Alessia ^a  

^a Santa Maria Nuova Istituto di Ricovero e Cura A Carattere Scientifico Hospital   (Italy)

^b Spedali Civili di Brescia   (Italy)

^c S MARIA NUOVA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; BRAF GENE; CANCER PATIENT; CONTROLLED STUDY; FEMALE; GENE ACTIVITY; GENE FUNCTION; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; ONCOGENE; PRIORITY JOURNAL; PYROSEQUENCING; THYROID CARCINOMA; THYROIDECTOMY; TUMOR GROWTH;

ADOLESCENT; ADULT; AGED; ALLELES; AMINO ACID SUBSTITUTION; CARCINOMA; CARCINOMA, PAPILLARY; DISEASE PROGRESSION; DNA MUTATIONAL ANALYSIS; EXONS; FEMALE; FOLLOW-UP STUDIES; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; HUMANS; ITALY; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; THYROID NEOPLASMS; YOUNG ADULT;

EID: 84877686708     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-3930     Document Type: Article

References (48)

1. Davies L, Welch HG. Thyroid cancer survival in the United States: observational data from 1973 to 2005. Arch Otolaryngol Head Neck Surg. 2010;136:440-444.
2. Caronia LM, Phay JE, Shah MH. Role of BRAF in thyroid oncogenesis. Clin Cancer Res. 2011;17:7511-7517.
3. Handkiewicz-Junak D, Czarniecka A, Jarzab B. Molecular prognostic markers in papillary and follicular thyroid cancer: current status and future directions. Mol Cell Endocrinol. 2010;322:8-28.
4. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003; 63:1454-1457.
5. Soares P, Trovisco V, Rocha AS, et al. BRAF mutations and RET/PTCrearrangements are alternative events in the etiopathogenesis of PTC. Oncogene. 2003;22:4578-4580.
6. Kebebew E, Weng J, Bauer J, et al. The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg. 2007;246: 466-471.
7. Lupi C, Giannini R, Ugolini C, et al. Association of BRAFV600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab. 2007;92:4085-4090.
8. Elisei R, Ugolini C, Viola D, et al. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15 year median follow-up study. J Clin Endocrinol Metab. 2008;93:3943-3949.
9. Elisei R, Viola D, Torregrossa L, et al. The BRAFV600E mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study. J Clin Endocrinol Metab. 2012;97:4390-4398.
10. Lin KL, Wang OC, Zhang XH, Dai XX, Hu XQ, Qu JM. The BRAF mutation is predictive of aggressive clinicopathology characteristics in papillary thyroid microcarcinoma. Ann Surg Oncol. 2010;17: 3294-3300.
11. Ricarte-Filho J, Ganly I, Rivera M, et al. Papillary thyroid carcinomas with cervical lymph node metastases can be stratified into clinically relevant prognostic categories using oncogenic BRAF, number of nodal metastasis and extra-nodal extension. Thyroid. 2012;22: 575-584.
12. Chakraborty A, Narkar A, Mukhopadhyaya R, Kane S, D'Cruz A, Rajan MG. BRAF (V600E) mutation in papillary thyroid carcinoma: significant association with node metastases and extra thyroidal invasion. Endocr Pathol. 2012;23:83-93.
13. Kim SJ, Lee KE, Myong JP, et al. BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer. World J Surg. 2012;36:310-317.
14. Lee JH, Lee ES, Kim YS. Clincopathologic significance of BRAFV600E mutation in papillary carcinomas of the thyroid: a meta-analysis. Cancer. 2007;110:38-46.
15. Kim TH, Park YJ, Lim JA, et al. The association of the BRAF (V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer. 2012; 118:1764-1773.
16. Li C, Lee KC, Schneider EB, Zeiger MA. BRAFV600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis. J Clin Endocrinol Metab. 2012;97:4559-4570.
17. Liu RT, Chen YJ, Chou FF, et al. No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan. Clin Endocrinol (Oxf). 2005;63: 461-466.
18. Fugazzola L, Puxeddu E, Avenia N, et al. Correlation between B-RAFV600Emutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocr Relat Cancer. 2006;13:455-464.
19. Ito Y, Yoshida H, Maruo R, et al. BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease free-survival. Endocr J. 2009;56:89-97.
20. Eloy C, Santos J, Soares P, Sobrinho-Simoes M. The preeminence of growth pattern and invasiveness and the limited influence of BRAF and RAS mutations in the occurrence of papillary thyroid carcinoma lymph node metastases. Virchows Arch. 2011;459:265-276.
21. Cheng S, Serra S, Mercado M, Ezzat S, Asa SL. A high throughput proteomic approach provides distinct signatures for thyroid cancer behaviour. Clin Cancer Res. 2011;17:2385-2394.
22. Paulson L, Shindo M, Schuff K, Corless C. The role of molecular markers and tumor histological type in central lymph node metastasis of papillary thyroid carcinoma. Arch Otolaryngol Head Neck Surg. 2012;138:44-49.
23. Sassolas G, Hafdi-Nejjari Z, Ferraro A, et al. Oncogenic alterations in papillary thyroid cancers of young patients. Thyroid. 2012;22: 17-26.
24. Ahn D, Park JS, Sohn JH, et al. BRAFV600Emutation does not serve as a prognostic factor in Korean patients with papillary thyroid carcinoma. Auris Nasus Larynx. 2012;39:198-203.
25. Nam JK, Jung CK, Song BJ, et al. Is the BRAF(V600E) mutation useful as a predictor of preoperative risk in papillary thyroid cancer? Am J Surg. 2012;203:436-441.
26. Lee KC, Li C, Schneider EB, et al. Is BRAF mutation associated with lymph node metastasis in patients with papillary thyroid cancer? Surgery. 2012;152:977-988.
27. Trovisco V, Soares P, Preto A, et al. Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness. Virchows Arch. 2005;446:589-595.
28. Trovisco V, Couto JP, Cameselle-Teijeiro J, et al. Acquisition of BRAF gene mutations is not a requirement for nodal metastasis of papillary thyroid carcinoma. Clin Endocrinol (Oxf). 2008;69:683-685.
29. Sancisi V, Nicoli D, Ragazzi M, Piana S, Ciarrocchi A. BRAFV600E mutation does not mean distant metastasis in thyroid papillary carcinomas. J Clin Endocrinol Metab. 2012;97:E1745-E1749.
30. Park YJ, Kim YA, Lee YJ, et al. Papillary microcarcinoma in comparison with larger papillary thyroid carcinoma in BRAF(V600E) mutation, clinicopathological features, and immunohistochemical findings. Head Neck. 2010;32:38-45.
31. Knauf JA, Ma X, Smith EP, et al. Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res. 2005; 65:4238-4245.
32. Guerra A, Sapio MR, Marotta V, et al. The primary occurrence of BRAF(V600E) is a rare clonal event in papillary thyroid carcinoma. J Clin Endocrinol Metab. 2012;97:517-524.
33. Guerra A, Fugazzola L, Marotta V, et al. A high percentage of BRAFV600Ealleles in papillary thyroid carcinoma predicts a poorer outcome. J Clin Endocrinol Metab. 2012;97:2333-2340.
34. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366:883-892.
35. De Lellis RA, Lloyd RV, Heitz PU, Eng C. World Health Organization Classification of Tumours. Pathology and Genetics of Tumors of Endocrine Organs. Lyon, France: IARC Press; 2004.
36. Edge SB, Byrd DR, Compton CC, Fritz AG. AJCC Cancer Staging Manual. 7th ed. New York: Springer; 2010.
37. Sancisi V, Borettini G, Maramotti S, et al. Runx2 isoform I controls a panel of proinvasive genes driving aggressiveness of papillary thyroid carcinomas. J Clin Endocrinol Metab. 2012;97:2006-2015.
38. Ciarrocchi A, Piana S, Valcavi R, Gardini G, Casali B. Inhibitor of DNA binding-1 induces mesenchymal features and promotes invasiveness in thyroid tumour cells. Eur J Cancer. 2011;47:934-945.
39. Sarne DH. A piece of the puzzle: what does BRAF status mean in the management of patients with papillary thyroid carcinoma? J Clin Endocrinol Metab. 2012;97:3094-3096.
40. Tufano RP, Bishop J, Wu G. Reoperative central compartment dissection for patients with recurrent/persistent papillary thyroid cancer: efficacy, safety, and the association of the BRAF mutation. Laryngoscope. 2012;122:1634-1640.
41. Piana S, Ragazzi M, Tallini G, et al. Papillary thyroid microcarcinoma with fatal outcome: evidence of tumor progression in lymph node metastases: report of 3 cases, with morphological and molecular analysis [published online October 15, 2012]. Hum Pathol. doi: 10.1016/j.humpath.2012.06.019.
42. Zheng X, Wei S, Han Y, et al. Papillary microcarcinoma of the thyroid: clinical characteristics and BRAF(V600E) mutational status of 977 cases [published online January 31, 2013]. Ann Surg Oncol. doi:10.1245/s10434-012- 2851-z.
43. Vasko V, Hu S, Wu G, et al. High prevalence and possible de novo formation of BRAF mutation in metastasized papillary thyroid cancer in lymph nodes. J Clin Endocrinol Metab. 2005;90:5265-5269.
44. Walch AK, Zitzelsberger HF, Bink K, et al. Molecular genetic changes in metastatic primary Barrett's adenocarcinoma and related lymph node metastases: comparison with nonmetastatic Barrett's adenocarcinoma. Mod Pathol. 2000;13:814-824.
45. Kim MA, Lee HJ Yang HK, Bang YJ, Kim WH. Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma. Histopathology. 2011;59:822-831.
46. Uchiyama C, Tamura S, Nakatsuka S, et al. Immunohistochemical consistency between primary tumors and lymph node metastases of gastric neuroendocrine carcinoma. World J Surg Oncol. 2012;10: 115.
47. Vredeveld LC, Possik PA, Smit MA, et al. Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis. Genes Dev. 2012;26:1055-1069.
48. Koperek O, Kornauth C, Capper D, et al. Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma. Am J Surg Pathol. 2012;36:844-850.